Literature DB >> 18716835

Racial differences in sarcoidosis granuloma density.

Robert R Burke1, Chad H Stone, Suzanne Havstad, Benjamin A Rybicki.   

Abstract

STUDY
OBJECTIVES: While sarcoidosis generally inflicts a greater morbidity on African-American compared with Caucasian patients, no studies have examined whether racial differences exist in the intensity of the histologic hallmark of sarcoidosis, noncaseating granulomas. DESIGN AND
SETTING: The study was conducted as a retrospective case series in a tertiary referral center. PATIENTS: The study included 187 patients with histopathologic confirmation of sarcoidosis by trans- and/or endobronchial biopsy between July 1991 and December 2001. MEASUREMENTS AND
RESULTS: Granuloma density was the average number of granulomas per biopsy piece on the slide with the most intense granulomatous inflammation at fourfold magnification. Overall, African-American patients had a twofold greater median granuloma density than Caucasians (p = 0.005). In a negative binomial multivariate model, radiographic pattern had the strongest association with granuloma density, with Scadding stage II and III patients having adjusted granuloma densities of 60% (p = 0.005) and 105% (p = 0.0001) higher than stage I patients. In the specific-tissue types, radiographic stage-adjusted granuloma densities in African-American patients were 49% greater in bronchial tissue (p = 0.03), but only a 27% greater in alveolar tissue (p = 0.51).
CONCLUSIONS: A greater granuloma density in bronchiolar lung tissue of African-American sarcoidosis patients may explain racial differences in diagnostic yield by lung biopsy and disease severity at diagnosis. This association persists even after controlling for Scadding radiographic stage, a measure of disease severity strongly associated with granuloma density.

Entities:  

Mesh:

Year:  2008        PMID: 18716835      PMCID: PMC4778712          DOI: 10.1007/s00408-008-9111-9

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  16 in total

Review 1.  Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.

Authors:  B A Rybicki; M Major; J Popovich; M J Maliarik; M C Iannuzzi
Journal:  Am J Epidemiol       Date:  1997-02-01       Impact factor: 4.897

2.  A new tool to assess sarcoidosis severity.

Authors:  Yasmine S Wasfi; Cecile S Rose; James R Murphy; Lori J Silveira; Jan C Grutters; Yoshikazu Inoue; Marc A Judson; Lisa A Maier
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

3.  Pulmonary sarcoidosis: spirometric correlation with transbronchial biopsy.

Authors:  D Gupta; V Jorapur; P Bambery; K Joshi; S K Jindal
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1997-03       Impact factor: 0.670

4.  Factors affecting outcome of sarcoidosis. Influence of race, extrathoracic involvement, and initial radiologic lung lesions.

Authors:  H L Israel; P Karlin; H Menduke; O G DeLisser
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

Review 5.  Racial and ethnic disparities in sarcoidosis: from genetics to socioeconomics.

Authors:  Gloria E Westney; Marc A Judson
Journal:  Clin Chest Med       Date:  2006-09       Impact factor: 2.878

6.  Clinical characteristics of patients in a case control study of sarcoidosis.

Authors:  R P Baughman; A S Teirstein; M A Judson; M D Rossman; H Yeager; E A Bresnitz; L DePalo; G Hunninghake; M C Iannuzzi; C J Johns; G McLennan; D R Moller; L S Newman; D L Rabin; C Rose; B Rybicki; S E Weinberger; M L Terrin; G L Knatterud; R Cherniak
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

Review 7.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

8.  Endobronchial biopsy for sarcoidosis: a prospective study.

Authors:  A F Shorr; K G Torrington; O W Hnatiuk
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

9.  The diagnostic pathway to sarcoidosis.

Authors:  Marc A Judson; Bruce W Thompson; David L Rabin; Joanne Steimel; Genell L Knattereud; Daniel T Lackland; Cecile Rose; Cynthia S Rand; Robert P Baughman; Alvin S Teirstein
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

10.  Histologic, microbiologic, and clinical correlates of the diagnosis of sarcoidosis by transbronchial biopsy.

Authors:  R M Hsu; A F Connors; J F Tomashefski
Journal:  Arch Pathol Lab Med       Date:  1996-04       Impact factor: 5.534

View more
  7 in total

Review 1.  Disease Burden and Variability in Sarcoidosis.

Authors:  Alicia K Gerke; Marc A Judson; Yvette C Cozier; Daniel A Culver; Laura L Koth
Journal:  Ann Am Thorac Soc       Date:  2017-12

2.  The Role of Endobronchial Biopsy in the Diagnosis of Pulmonary Sarcoidosis.

Authors:  Tuğba Göktalay; Pınar Çelik; Aylin Özgen Alpaydın; Yavuz Havlucu; Ayşın Şakar Coşkun; Aydın Işısağ; Arzu Yorgancıoğlu
Journal:  Turk Thorac J       Date:  2015-12-14

3.  The Assessment of Cough in a Sarcoidosis Clinic Using a Validated instrument and a Visual Analog Scale.

Authors:  Marc A Judson; Amit Chopra; Edward Conuel; Efstratios Koutroumpakis; Christopher Schafer; Adam Austin; Robert Zhang; Kerry Cao; Rani Berry; Malik M H S Khan; Aakash Modi; Ritu Modi; Stephanie Jou; Furqan Ilyas; Recai M Yucel
Journal:  Lung       Date:  2017-07-13       Impact factor: 2.584

4.  Mathematical model of sarcoidosis.

Authors:  Wenrui Hao; Elliott D Crouser; Avner Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

5.  Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease.

Authors:  Karen C Patterson; Beverly S Franek; Joachim Müller-Quernheim; Anne I Sperling; Nadera J Sweiss; Timothy B Niewold
Journal:  Cytokine       Date:  2013-02-04       Impact factor: 3.861

6.  Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis.

Authors:  Dashant Kavathia; John D Buckley; Dhanwada Rao; Benjamin Rybicki; Robert Burke
Journal:  Respir Med       Date:  2010-01-13       Impact factor: 3.415

7.  A genome-wide admixture scan for ancestry-linked genes predisposing to sarcoidosis in African-Americans.

Authors:  B A Rybicki; A M Levin; P McKeigue; I Datta; C Gray-McGuire; M Colombo; D Reich; R R Burke; M C Iannuzzi
Journal:  Genes Immun       Date:  2010-12-23       Impact factor: 2.676

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.